Roivant Sciences Ltd. (NASDAQ:ROIV) Holdings Boosted by Creative Planning

Creative Planning boosted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 47.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,541 shares of the company’s stock after acquiring an additional 7,579 shares during the period. Creative Planning’s holdings in Roivant Sciences were worth $272,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. nVerses Capital LLC bought a new position in Roivant Sciences in the second quarter worth about $34,000. Point72 Hong Kong Ltd acquired a new stake in shares of Roivant Sciences in the second quarter valued at approximately $36,000. Quarry LP acquired a new stake in shares of Roivant Sciences in the second quarter valued at approximately $53,000. Acadian Asset Management LLC acquired a new stake in shares of Roivant Sciences in the first quarter valued at approximately $72,000. Finally, Fifth Third Wealth Advisors LLC acquired a new stake in shares of Roivant Sciences in the second quarter valued at approximately $101,000. Institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ROIV. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Thursday, September 19th. Finally, Bank of America raised their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $17.39.

Insider Buying and Selling

In related news, Director Financial Lp Qvt sold 876,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $11.82, for a total value of $10,354,320.00. Following the completion of the transaction, the director now owns 22,179,358 shares of the company’s stock, valued at approximately $262,160,011.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Roivant Sciences news, Director Financial Lp Qvt sold 876,000 shares of Roivant Sciences stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $11.82, for a total transaction of $10,354,320.00. Following the completion of the sale, the director now owns 22,179,358 shares of the company’s stock, valued at $262,160,011.56. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Rakhi Kumar sold 250,000 shares of Roivant Sciences stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $11.89, for a total transaction of $2,972,500.00. Following the sale, the chief accounting officer now directly owns 209,322 shares of the company’s stock, valued at $2,488,838.58. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,577,309 shares of company stock valued at $42,151,184. Company insiders own 7.90% of the company’s stock.

Roivant Sciences Trading Up 0.9 %

Roivant Sciences stock opened at $11.87 on Friday. The company has a 50 day moving average price of $11.79 and a 200 day moving average price of $11.29. Roivant Sciences Ltd. has a 52 week low of $8.47 and a 52 week high of $13.06. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. The firm has a market capitalization of $8.78 billion, a price-to-earnings ratio of 2.13 and a beta of 1.24.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The firm had revenue of $55.10 million during the quarter, compared to analyst estimates of $30.72 million. During the same quarter last year, the business posted ($0.38) EPS. The company’s revenue was up 155.1% on a year-over-year basis. Research analysts forecast that Roivant Sciences Ltd. will post -1.14 EPS for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.